F. Lofts

9.3k total citations · 1 hit paper
45 papers, 6.3k citations indexed

About

F. Lofts is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, F. Lofts has authored 45 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 15 papers in Surgery and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in F. Lofts's work include Pancreatic and Hepatic Oncology Research (8 papers), Colorectal Cancer Treatments and Studies (8 papers) and Gastric Cancer Management and Outcomes (6 papers). F. Lofts is often cited by papers focused on Pancreatic and Hepatic Oncology Research (8 papers), Colorectal Cancer Treatments and Studies (8 papers) and Gastric Cancer Management and Outcomes (6 papers). F. Lofts collaborates with scholars based in United Kingdom, United States and Denmark. F. Lofts's co-authors include David Cunningham, Timothy Iveson, M. Nicolson, Stephen Falk, Simon Weeden, Ruth E. Langley, David B. Smith, J N Thompson, Yu Jo Chua and Sally Stenning and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The EMBO Journal.

In The Last Decade

F. Lofts

45 papers receiving 6.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer

2006 4.5k citations David Cunningham, William Allum et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by F. Lofts

Since Specialization

Citations

This map shows the geographic impact of F. Lofts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Lofts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Lofts more than expected).

Fields of papers citing papers by F. Lofts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Lofts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Lofts. The network helps show where F. Lofts may publish in the future.

Co-authorship network of co-authors of F. Lofts

This figure shows the co-authorship network connecting the top 25 collaborators of F. Lofts. A scholar is included among the top collaborators of F. Lofts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Lofts. F. Lofts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors 2020 ·International Journal of Gynecological Cancer ·Rosemary Lord, (unknown), Tamsin Morris, (unknown), Rachel Jones, Rowan Miller, Marcia Hall, F. Lofts, Rosalind Glasspool, Emma Hudson	3
2	Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases 2015 ·Thrombosis Research ·(unknown), Heleen J. van Beekhuizen, Vivek Nama, (unknown), Marielle Nobbenhuis, Thomas Ind, S.A. Sohaib, F. Lofts, Sue Heenan, Martin Gore, Susana Banerjee, Stan B. Kaye, Desmond P.J. Barton	14
3	Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer 2011 ·European Journal of Cancer ·Anthony Maraveyas, Justin S. Waters, Rajarshi Roy, D. Fyfe, David Propper, F. Lofts, Joseph Sgouros, Eric Gardiner, K R Wedgwood, Camille Ettelaie, George Bozas	234
4	Can localised 19F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response? 2010 ·Cancer Chemotherapy and Pharmacology ·Dominick J. O. McIntyre, Franklyn A. Howe, Christophe Ladroue, F. Lofts, Marion Stubbs, John R. Griffiths	10
5	Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study 2009 ·British Journal of Cancer ·Juan W. Valle, Harpreet Wasan, Philip J. Johnson, Elizabeth Jones, L. Dixon, R. Swindell, Sofia Baka, Anthony Maraveyas, Pippa Corrie, Stephen Falk, Simon Gollins, F. Lofts, Linda Evans, Tim Meyer, Alan Anthoney, Timothy Iveson, Martin Highley, Richard H. Osborne, John Bridgewater	202
6	Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer breakdown → 2006 ·New England Journal of Medicine ·David Cunningham, William Allum, Sally Stenning, J N Thompson, Cornelis J.�H. van de Velde, M. Nicolson, J.H. Scarffe, F. Lofts, Stephen Falk, Timothy Iveson, David B. Smith, Ruth E. Langley, Monica Verma, Simon Weeden, Yu Jo Chua	4494
7	Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study 2006 ·Gynecologic Oncology ·Christopher Steer, K. Chrystal, (unknown), Eleni Galani, Gavin Marx, A. H. Strickland, Desmond Yip, F. Lofts, C. Gallagher, H. Thomas, Peter Harper	9
8	13-cis-Retinoic Acid in Combination with Gemcitabine in the Treatment of Locally Advanced and Metastatic Pancreatic Cancer — Report of a Pilot Phase II Study 2006 ·Clinical Oncology ·Agnieszka Michael, Mark Hill, Anthony Maraveyas, Angus Dalgleish, F. Lofts	30
9	A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer 2005 ·Annals of Oncology ·Ian Chau, A. Norman, David Cunningham, Diana Tait, Paul J. Ross, Timothy Iveson, Mark Hill, Tamas Hickish, F. Lofts, Duncan I. Jodrell, Andrew Webb, J. Oates	135
10	Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer 2005 ·European Journal of Cancer ·Ian Chau, A. Norman, David Cunningham, Timothy Iveson, Mark Hill, Tamas Hickish, F. Lofts, Duncan I. Jodrell, Andrew Webb, Diana Tait, Paul J. Ross, (unknown), J. Oates	18
11	Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer 2003 ·British Journal of Cancer ·Andrea Saini, A. Norman, David Cunningham, Ian Chau, Mark Hill, Diana Tait, Tamas Hickish, Timothy Iveson, F. Lofts, Duncan I. Jodrell, Paul J. Ross, J. Oates	61
12	A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer 2002 ·British Journal of Cancer ·T.R. Jeffry Evans, K W Colston, F. Lofts, David Cunningham, Alan Anthoney, Helen Gogas, Johann S. de Bono, (unknown), Torsten Skov, Janine Mansi	106
13	A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus 2002 ·Annals of Oncology ·Justin S. Waters, Diana Tait, David Cunningham, Anwar R. Padhani, Mark Hill, Stephen Falk, F. Lofts, A. Norman, J. Oates, A Hill	9
14	A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma 2001 ·Annals of Oncology ·Helen Mackay, Alistair McInnes, James Paul, Nigel Raby, F. Lofts, A. McDonald, M. Soukop, G M Fullarton, Adrian L. Harris, J. Garcia‐Vargas, T.R. Jeffry Evans	18
15	A phase II study of tomudex (T) in combination with epirubicin (E) and cisplatin (C) in patients with advanced oesophageal and gastric (OG) adenocarcinoma. 2000 ·Annals of Oncology ·Helen Mackay, Alyson W. MacInnes, (unknown), Nigel Raby, F. Lofts, M. Soukop, Andrew Harris, (unknown), J. Garcia‐Vargas, J. Evans	5
16	Management of adenocarcinoma of unknown primary with a 5-fluorouracil-cisplatin chemotherapy regimen (CFTam) 1999 ·Annals of Oncology ·F. Lofts, Helen Gogas, Janine Mansi	14
17	Bile duct stents: Is there an increased rate of complications in patients receiving chemotherapy? 1997 ·European Journal of Cancer ·F. Lofts, T.R. Jeffry Evans, Janine Mansi, J.P. Glees, (unknown)	17
18	Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo. 1993 ·PubMed ·F. Lofts, Helen C. Hurst, Michael J.E. Sternberg, WJ Gullick	55
19	c-erb B2 amplification and overexpression in human tumors 1991 ·Cancer treatment and research ·F. Lofts, William J. Gullick	35
20	Treatment with danazol and plasma glucagon concentration. 1985 ·BMJ ·Gareth Williams, F. Lofts, (unknown), S Bloom	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact